uniQure shares fall after weaker AMT-130 four-year data
In short
uniQure shares fell after new four-year data for its Huntington’s gene therapy AMT-130. The update said the slowing of disease progression was weaker than earlier results, even though 48-month TFC data was still encouraging and the cUHDRS result was not statistically significant.
This matters because investors are watching the FDA review and whether the treatment’s earlier benefits last. The report does not say what the FDA will decide.
What the reporting says
uniQure shares plunged after four-year data on Huntington’s gene therapy AMT-130 showed weaker disease-progression slowing than earlier results. The summary says 48-month TFC data remained encouraging, but the cUHDRS effect was not statistically significant. Investors are now focused on FDA review and on whether earlier benefits can hold over time, while the reporting does not state the final regulatory outcome.
Why it matters
The market reaction follows updated four-year data for uniQure’s Huntington’s gene therapy AMT-130. According to the summary, the therapy still showed encouraging 48-month TFC data, but the cUHDRS effect was not statistically significant and the disease-slowing benefit looked weaker than earlier results. That combination has raised investor concern ahead of FDA review, though the available reporting does not state the regulator’s view or any approval timeline.